SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ 1999 Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 35403545.
  • 2
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165176.
  • 3
    Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345357.
  • 4
    Takahashi N, Udagawa N, Suda T 1999 A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 256: 449455.
  • 5
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, Mochizuki SI, Tsuda E, Morinaga T, Udagawa N, Takahashi N, Suda T, Higashio K 1999 A novel molecular mechanism modulating osteoclast differentiation and function. Bone 25: 109113.
  • 6
    Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423: 337342.
  • 7
    Lee ZH, Kim HH 2003 Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 305: 211214.
  • 8
    Coleman RA, Smith WL, Narumiya S 1994 International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46: 205229.
  • 9
    Breyer RM, Bagdassarian CK, Myers SA, Breyer MD 2001 Prostanoid receptors: Subtypes and signaling. Annu Rev Pharmacol Toxicol 41: 661690.
  • 10
    Tsuboi K, Sugimoto Y, Ichikawa A 2002 Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat 68–69: 535556.
  • 11
    Li X, Okada Y, Pilbeam CC, Lorenzo JA, Kennedy CR, Breyer RM, Raisz LG 2000 Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology 141: 20542061.
  • 12
    Miyaura C, Inada M, Suzawa T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Suda T 2000 Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J Biol Chem 275: 1981919823.
  • 13
    Ono K, Akatsu T, Murakami T, Nishikawa M, Yamamoto M, Kugai N, Motoyoshi K, Nagata N 1998 Important role of EP4, a subtype of prostaglandin (PG) E receptor, in osteoclast-like cell formation from mouse bone marrow cells induced by PGE2. J Endocrinol 158: R1R5.
  • 14
    Sakuma Y, Tanaka K, Suda M, Yasoda A, Natsui K, Tanaka I, Ushikubi F, Narumiya S, Segi E, Sugimoto Y, Ichikawa A, Nakao K 2000 Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner Res 15: 218227.
  • 15
    Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Suda T 2000 The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: An analysis using specific agonists for the respective EPs. Endocrinology 141: 15541559.
  • 16
    Inoue H, Tsujisawa T, Fukuizumi T, Kawagishi S, Uchiyama C 1999 SC-19220, a prostaglandin E2 antagonist, inhibits osteoclast formation by 1,25-dihydroxyvitamin D3 in cell cultures. J Endocrinol 161: 231236.
  • 17
    Sanner J 1971 Prostaglandin inhibition with a dibenzoxazepine hydrazide derivative and morphine. Ann NY Acad Sci 180: 396409.
  • 18
    Rakovska A, Milenov K 1984 Antagonistic effect of SC-19220 on the responses of guinea-pig gastric muscles to prostaglandins E1, E2 and F2 alpha. Arch Int Pharmacodyn Ther 268: 5969.
  • 19
    Coleman RA, Kennedy I 1985 Characterisation of the prostanoid receptors mediating contraction of guinea-pig isolated trachea. Prostaglandins 29: 363375.
  • 20
    Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S 1997 Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 122: 217224.
  • 21
    Kobayashi T, Narumiya S 2002 Function of prostanoid receptors: Studies on knockout mice. Prostaglandins Other Lipid Mediat 68–69: 557573.
  • 22
    Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T 2000 Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191: 275286.
  • 23
    Fujita D, Yamashita N, Iita S, Amano H, Yamada S, Sakamoto K 2003 Prostaglandin E(2) induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. Prostaglandins Leukot Essent Fatty Acids 68: 351358.
  • 24
    Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T 1999 Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190: 17411754.
  • 25
    Stanley ER 1992 Colony-stimulating factor-1. In: AggorwalBB, GuttermanJU (eds.) Human Cytokines. Blackwell Scientific Publications, Boston, MA, USA, p. 196220
  • 26
    Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, Choi Y 1999 TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 4: 10411049.
  • 27
    Courtneidge SA, Dhand R, Pilat D, Twamley GM, Waterfield MD, Roussel MF 1993 Activation of Src family kinases by colony stimulating factor-1, and their association with its receptor. EMBO J 12: 943950.
  • 28
    Alonso G, Koegl M, Mazurenko N, Courtneidge SA 1995 Sequence requirements for binding of Src family tyrosine kinases to activated growth factor receptors. J Biol Chem 270: 98409848.
  • 29
    Reedijk M, Liu X, van der Geer P, Letwin K, Waterfield MD, Hunter T, Pawson T 1992 Tyr721 regulates specific binding of the CSF-1 receptor kinase insert to PI 3′-kinase SH2 domains: A model for SH2-mediated receptor-target interactions. EMBO J 11: 13651372.
  • 30
    Bourette RP, Myles GM, Choi JL, Rohrschneider LR 1997 Sequential activation of phoshatidylinositol 3-kinase and phospholipase C-gamma2 by the M-CSF receptor is necessary for differentiation signaling. EMBO J 16: 58805893.
  • 31
    Soriano P, Montgomery C, Geske R, Bradley A 1991 Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64: 693702.
  • 32
    Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P 1993 Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA 90: 44854489.
  • 33
    Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR 1992 Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 90: 16221627.
  • 34
    Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R 1997 Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 3: 12851289.
  • 35
    Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T 2002 Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889901.
  • 36
    Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y, Kumegawa M, Kimura T, Takeya T 2002 Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 277: 4114741156.
  • 37
    Shui C, Riggs BL, Khosla S 2002 The immunosuppressant rapamycin, alone or with transforming growth factor-beta, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand. Calcif Tissue Int 71: 437446.
  • 38
    Hirotani H, Tuohy NA, Woo JT, Stern PH, Clipstone NA 2004 The calcineurin/NFAT signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem 279: 1398413992.
  • 39
    Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, Taniguchi T, Takayanagi H 2004 Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428: 758763.
  • 40
    Watabe A, Sugimoto Y, Honda A, Irie A, Namba T, Negishi M, Ito S, Narumiya S, Ichikawa A 1993 Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. J Biol Chem 268: 2017520178.
  • 41
    Guan Y, Zhang Y, Breyer RM, Fowler B, Davis L, Hebert RL, Breyer MD 1998 Prostaglandin E2 inhibits renal collecting duct Na+ absorption by activating the EP1 receptor. J Clin Invest 102: 194201.
  • 42
    Harris TE, Squires PE, Michael AE, Bernal AL, Abayasekara DR 2001 Human granulosa-lutein cells express functional EP1 and EP2 prostaglandin receptors. Biochem Biophys Res Commun 285: 10891094.